Angiotensin receptors and their antagonists

New England Journal of Medicine

Volumn 334, Issue 25, 1996, Pages 1649-1654

  Goodfriend, Theodore L ^a,c   Elliott, Mary E ^a   Catt, Kevin J ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

DRUG MECHANISM; EMBRYO DEVELOPMENT; GROWTH REGULATION; HEART FAILURE; HEART HYPERTROPHY; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; HYPERTENSION; PHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSINS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 0030594604     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199606203342507     Document Type: Article

References (81)

1. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992;10:S13-S26.
2. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11:Suppl F:13F-19F.
3. Gavras I, Gavras H. Angiotensin II - possible adverse effects on arteries, heart, brain, and kidney: experimental, clinical, and epidemiological evidence. In: Robertson JIS, Nicholls MG, eds. The renin-angiotensin system. Vol. I. Biochemistry/physiology. London: Cower Medical Publishing, 1993: 40.1-40.11.
4. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995;25:924-7.
5. Bohr DF. Angiotensin on vascular smooth muscle. In: Page IH, Bumpus FM, eds. Angiotensin. Vol. 37 of Handbook of experimental pharmacology. New York: Springer-Verlag, 1974:424-40.
6. Griffin SA, Brown WC, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17: 626-35.
7. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA 1960;174:234-40.
8. Ménard J, Guyene T-T. Chatellier G, Kleinbloesem CH, Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 1991;18:257-65.
9. Mitchell KD, Braam B, Navar LG. Hypertensinogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension 1992;19: Suppl:I-18-I-27.
10. Hall JE, Granger JP. Renal hemodynamic actions of angiotensin II: interaction with tubuloglomerular feedback. Am J Physiol 1983;245:R166-R173.
11. McGiff JC, Crowshaw K, Terragno NA, Lonigro AJ. Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res 1970;27:Suppl 1:121-30.
12. Tufro-McReddie A, Johns DW, Geary KM, et al. Angiotensin II type 1 receptor: role in renal growth and gene expression during normal development. Am J Physiol 1994;266:F911-F918.
13. 1 receptor mRNA in rat kidney. Kidney Int 1994;46:973-9.
14. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev 1992;13:329-80.
15. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262:E763-E778.
16. Foucart S, de Champlain J. Nadeau R. Modulation by beta-adrenoceptors and angiotensin II receptors of splanchnic nerve evoked catecholamine release from the adrenal medulla. Can J Physiol Pharmacol 1991;69:1-7.
17. Kent KM, Goodfriend TL, McCallum ZT, Dempsey PJ, Cooper T. Inotropic agents in hypoxic cat myocardium: depression and potentiation. Circ Res 1972;30:196-204.
18. Moravec CS, Schluchter MD, Paranandi L, et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990;82:1973-84.
19. 1 receptor subtype. Circ Res 1993;73:413-23.
20. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18: Suppl:II-100-II-105.
21. Gorbea-Oppliger VJ, Melaragno MG, Potter GS, Petit RL, Fink GD. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. J Pharmacol Exp Ther 1994;271:804-10.
22. Lin S-Y, Goodfriend TL. Angiotensin receptors. Am J Physiol 1970;218: 1319-28.
23. Goodfriend T, Knych E, Lin S-Y, Henry R. Direct measurement of receptor binding - a screening procedure for angiotensin inhibitors. Clin Pharmacol Ther 1971;12:292. abstract.
24. Carini DJ, Duncia JV, Aldrich PE, et al. Nonpeplide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem 1991;34:2525-47.
25. Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991;351:230-3.
26. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-6.
27. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.
28. Szpirer C, Riviere M, Szpirer J, et al. Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. J Hypertens 1993;11:919-25.
29. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun 1994;203:1842-50.
30. 1 receptor. J Biol Chem 1994;269:30953-9.
31. Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis. Biochem Biophys Res Commun 1992;189:677-83.
32. Catt KJ, Sandberg K, Balla T. Angiotensin II receptor and signal transduction mechanisms. In: Raizada MK, Phillips MI, Sumners C, eds. Cellular and molecular biology of the renin-angiotensin system. Boca Raton, Fla.: CRC Press, 1993:307-56.
33. Spät A, Enyedi P, Hajnoczky G, Hunyady L. Generation and role of calcium signal in adrenal glomerulosa cells. Exp Physiol 1991;76:859-85.
34. Tsuda T, Griendling KK, Ollerenshaw JD, Lassegue B, Alexander RW. Angiotensin-II- and endothelin-induced protein phosphorylation in cultured vascular smooth muscle cells. J Vasc Res 1993;30:241-9.
35. 1A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem 1994;269:31443-9.
36. 2 receptor: searching for signal-transduclion pathways and physiological function. Trends Pharmacol Sci 1995;16:223-5.
37. 1 angiotensin receptor. J Biol Chem 1994;269:31378-82.
38. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonist-induced phosphorylation of the vascular type I angiotensin II receptor. Hypertension 1994;24:523-7.
39. Goodfriend TL, Ball DL, Elliott ME, Morrison AR, Evenson MA. Fatly acids are potential endogenous regulators of aldosterone secretion. Endocrinology 1991;128:2511-9.
40. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
41. Chen L, McNeill JR, Wilson TW, Gopalakrishnan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension 1995;26:83-8.
42. Lin L, Nasjletti A. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension 1991;18:158-64.
43. Berk BC, Rao GN. Angiotensin II-induced vascular smooth muscle cell hypertrophy: PDGF A-chain mediates the increase in cell size. J Cell Physiol 1993;154:368-80.
44. Stern N, Yanagawa N, Saito F, et al. Potential role of 12 hydroxyeicosatetraenoic acid in angiotensin II-induced calcium signal in rat glomerulosa cells. Endocrinology 1993;133:843-7.
45. Brown CE, Gant NF, Cox K, Spitz B, Rosenfeld CR, Magness RR. Low-dose aspirin. II. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome. Am J Obstet Gynecol 1990;163:1853-61.
46. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type I receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
47. Williams GH. Essential hypertension as an endocrine disease. Endocrinol Metab Clin North Am 1994;23:429-44.
48. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8.
49. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.
50. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-35.
51. Streeten DHP, Anderson GH Jr. Outpatient experience with saralasin. Kidney Int 1979;15:Suppl 9:S-44-S-52.
52. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
53. 1 angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994;269:16533-6.
54. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
55. Brunner HR, Delacrétaz E, Nussberger J, Burnier M, Waeber B. Angiotensin II antagonists DuP 753 and TCV 116. J Hypertens Suppl 1994;12:S29-S34.
56. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-11. [Erratum. Arch Intern Med 1995;155:876.]
57. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.
58. Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
59. 8]A II) and to inhibition of converting enzyme (captopril). Circulation 1980;61:163-9.
60. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22: 339-47.
61. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
62. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin 1 converting enzyme inhibition. Kidney Int 1993; 44:545-50.
63. Kabour A, Henegar JR, Janicki JS. Angiotensin II (AII)-induced myocyte necrosis: role of the All receptor. J Cardiovasc Pharmacol 1994;23:547-53.
64. Weber KT, Sun Y, Cleutjens JPM. Structural remodeling of the myocardium postinfarction: potential mechanisms and influence of therapy. Cardiol Rev 1995;3:53-65.
65. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-7.
66. 1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol 1994;23:291-9.
67. Balla T, Baukal AJ, Eng S, Catt KJ. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol Pharmacol 1991;40:401-6.
68. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5.
69. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 1994;35:1378-85.
70. Vandekerckhove A, Keppens S, De Wulf H. The angiotensin II receptor of rabbit liver: characterization in isolated hepalocytes and effect of GTP. J Endocrinol 1989;123:131-6.
71. Schinke M, Doods HN, Ganten D, Wienen W, Entzeroth M. Characterization of rat intestinal angiotensin II receptors. Eur J Pharmacol 1991;204: 165-70.
72. 1 receptor activation. J Clin Endocrinol Metab 1995;80:1233-7.
73. Swartz SL, Moore TJ. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 1990;63:87-90.
74. Aguilera G, Millan MA, Harwood JP. Angiotensin II receptors in the gonads. Am J Hypertens 1989;2:395-402.
75. 1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 1994;112:435-42.
76. Vinson GP, Puddefoot JR, Ho MM, et al. Type I angiotensin II receptors in rat and human sperm. J Endocrinol 1995;144:369-78.
77. Kunert-Radek J, Stepien H, Komorowski J, Pawlikowski M. Stimulatory effect of angiotensin II on the proliferation of mouse spleen lymphocytes in vitro is mediated via both types of angiotensin II receptors. Biochem Biophys Res Commun 1994;198:1034-9,
78. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25: 37-46.
79. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther 1993;265:664-73.
80. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: functional implications. Front Neuroendocrinol 1995;16:23-52.
81. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.